{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/prescribing-information/sglt-2-inhibitors/","result":{"pageContext":{"chapter":{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors","depth":2,"htmlHeader":"<!-- begin field 2ef37342-7bae-4d5e-8c09-a77100a954fa --><h2>SGLT-2 inhibitors</h2><!-- end field 2ef37342-7bae-4d5e-8c09-a77100a954fa -->","summary":"","htmlStringContent":"<!-- begin item a1920540-f806-45ab-b1a7-a77100a95070 --><!-- end item a1920540-f806-45ab-b1a7-a77100a95070 -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d523d81b-eb43-525f-8419-3a5b5111a7fc","slug":"recommended-doses","fullItemName":"Recommended doses","depth":3,"htmlHeader":"<!-- begin field bcfbf8db-8878-4e23-a6db-a77100ab08ab --><h3>Recommended doses</h3><!-- end field bcfbf8db-8878-4e23-a6db-a77100ab08ab -->","summary":"","htmlStringContent":"<!-- begin item 8aac7ba6-7ebd-4dec-aac1-a77100ab068a --><!-- begin field a9a3af75-a8f7-480c-8f5f-a77100ab08ab --><p><strong>There are four SGLT-2 inhibitors available in the UK. The recommended doses are:</strong></p><ul><li>Canagliflozin<ul><li>Recommended starting dose is 100 mg once daily, increased to 300 mg once daily if needed, dose to be taken preferably before breakfast.</li></ul></li><li>Dapagliflozin<ul><li>Recommended dose is 10 mg once daily.</li></ul></li><li>Empagliflozin<ul><li>Recommended starting dose is 10 mg once daily, increased to 25 mg once daily if needed and tolerated.</li></ul></li><li>Ertuglifozin<ul><li>Recommended starting dose is 5 mg once daily, increased to 15 mg once daily if needed and tolerated, dose to be taken in the morning.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field a9a3af75-a8f7-480c-8f5f-a77100ab08ab --><!-- end item 8aac7ba6-7ebd-4dec-aac1-a77100ab068a -->","subChapters":[]},{"id":"ee649e9f-3c2e-561b-ad4a-ddce5e011880","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 6946a0a3-287f-4879-8aec-a77100ab4726 --><h3>Contraindications and cautions</h3><!-- end field 6946a0a3-287f-4879-8aec-a77100ab4726 -->","summary":"","htmlStringContent":"<!-- begin item 8cc4664d-8952-404c-98e5-a77100ab44ec --><!-- begin field e527f592-80dc-4557-b8e2-a77100ab4726 --><ul><li> <strong>Do not prescribe an SGLT-2 inhibitor to people with:</strong><ul><li>Diabetic ketoacidosis (DKA) — serious and potentially life-threatening cases of DKA have been reported in people taking SGLT-2 inhibitors. Advise to stop treatment immediately and seek medical advice if any clinical features of DKA develop.</li><li>Moderate-to-severe renal impairment — avoid initiation if estimated glomerular filtration rate (eGFR) is less than 60 mL/min/1.73 m<sup>2</sup>; avoid continuation if eGFR is less than 45 mL/min/1.73 m<sup>2</sup> (use low-dose canagliflozin and empagliflozin if the eGFR persistently falls below 60 mL/min/1.73 m<sup>2</sup>). Monitor renal function at least twice yearly if moderate renal impairment.</li><li>Severe hepatic impairment — manufacturer advises to avoid canagliflozin, empagliflozin, and ertugliflozin.</li><li>Increasing age — avoid empagliflozin if aged over 85 years, as risk of volume depletion.</li><li>Active foot disease (such as skin ulceration, osteomyelitis, or gangrene) — possible increased risk of lower limb amputation (mainly toes) with canagliflozin. Advise to stop treatment if signs of a foot complication develop, such as skin ulceration, discolouration, infection, or new pain/tenderness, and seek urgent medical assessment.</li></ul></li><li><strong>Prescribe an SGLT-2 inhibitor with caution in people with:</strong><ul><li>Severe hepatic impairment — manufacturer advises caution with dapagliflozin and to start at lower 5 mg once daily dose; increase to 10 mg once daily if tolerated.</li><li>History of foot ulcer, peripheral arterial disease, or lower limb amputation — increased risk of lower limb amputation (mainly toes) with canagliflozin. Advise to stop treatment if signs of a foot complication such as skin ulceration, discolouration, infection, or new pain/tenderness, and seek urgent medical assessment.</li><li>Increasing age, hypotension — risk of volume depletion.</li><li>Complicated urinary tract infection — consider temporarily stopping empagliflozin treatment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field e527f592-80dc-4557-b8e2-a77100ab4726 --><!-- end item 8cc4664d-8952-404c-98e5-a77100ab44ec -->","subChapters":[]},{"id":"31dd9189-827c-58d0-99b0-5356b0d4001f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1b69a96f-a55f-4d10-bd67-a77100ab6515 --><h3>Adverse effects</h3><!-- end field 1b69a96f-a55f-4d10-bd67-a77100ab6515 -->","summary":"","htmlStringContent":"<!-- begin item 737beedc-bbd7-4ea1-b386-a77100ab5a7c --><!-- begin field 377a8556-0ee1-41c1-bf1a-a77100ab6515 --><p><strong>Possible adverse effects of SGLT-2 inhibitors include:</strong></p><ul><li>Vulvovaginitis, balanoposthitis, urinary tract infection or urosepsis.</li><li>Fournier’s gangrene — this is a rare but potentially life-threatening necrotizing fasciitis of the genitalia and perineum (predominantly in men). May present as severe pain or tenderness, erythema, and swelling in the genital or perineal area, with fever or malaise.  Advise to stop the SGLT-2 inhibitor immediately and seek immediate medical assessment if suspected.</li><li>Constipation, nausea, thirst, dyslipidaemia, hypotension, syncope.</li><li>Lower limb amputation (canagliflozin).</li><li>Renal impairment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">MHRA, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 377a8556-0ee1-41c1-bf1a-a77100ab6515 --><!-- end item 737beedc-bbd7-4ea1-b386-a77100ab5a7c -->","subChapters":[]},{"id":"cf04c5df-4c97-51ac-8f4d-122956478acf","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 5c4cff7c-edad-4e10-b7f0-a77100abc4f2 --><h3>Drug interactions</h3><!-- end field 5c4cff7c-edad-4e10-b7f0-a77100abc4f2 -->","summary":"","htmlStringContent":"<!-- begin item e8d9bf3b-16f9-47fb-ba43-a77100abc2c1 --><!-- begin field f62620a9-4073-4184-a013-a77100abc4f2 --><ul><li><strong>Possible drug interactions with SGLT-2 inhibitors include:</strong><ul><li>Thiazide and loop diuretics — additive effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension.</li><li>Insulin and insulin secretagogues (such as sulphonylureas) — cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue (such as a sulfonylurea) may be required to reduce the risk of hypoglycaemia.</li><li>Enzyme-inducers (such as St John's wort, rifampicin, barbiturates, phenytoin, carbamazepine, ritonavir, efavirenz) — may decrease the efficacy of canagliflozin.</li><li>Digoxin — risk of digoxin toxicity, monitored appropriately.</li><li>Dabigatran — dabigatran concentrations may be increased with canagliflozin. Monitor for signs of bleeding or anaemia when dabigatran is combined with canagliflozin.</li><li>Cholestyramine — may potentially reduce canagliflozin exposure. Dosing of canagliflozin should occur at least 1 hour before or 4–6 hours after administration of a bile acid sequestrant, to minimize possible interference with absorption.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field f62620a9-4073-4184-a013-a77100abc4f2 --><!-- end item e8d9bf3b-16f9-47fb-ba43-a77100abc2c1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}